Long-Term Cardiovascular Risk in Patients With ANOCA: A Clinical Reality to Consider?

Chronic stable angina (CSA) remains one of the most frequent reasons for referral to diagnostic coronary angiography (CAG). In a substantial proportion of these patients, no obstructive coronary lesions or stenoses are identified, a condition referred to as angina with no obstructive coronary arteries (ANOCA). This group has been considered to be at higher cardiovascular risk (CVR), mainly due to persistent symptoms, a high burden of cardiovascular risk factors, and the potential presence of microvascular dysfunction or vasospasm. However, long-term evidence comparing their prognosis with that of the general population remains limited.

Pronóstico al año en lesiones ateroscleróticas vs las no ateroscleróticas en pacientes con MINOCA

In this context, the study by Olesen et al. provides long-term follow-up data aimed at evaluating 15-year CVR in patients with ANOCA referred for CAG due to stable angina, compared with a cohort from the general population. Data were obtained from Danish national registries and included patients ≥18 years of age who underwent elective CAG for suspected CSA between 2003 and 2021, in whom the absence of obstructive coronary artery disease (stenosis <50%) and no prior history of myocardial infarction (MI) were documented, thus defining the ANOCA cohort.

Each ANOCA case was matched in a 1:5 ratio by age and sex with individuals from the general population without a history of cardiovascular disease. The maximum follow-up was 15 years, with a mean follow-up of 10.7 years. Evaluated outcomes included MI, ischemic stroke, and all-cause mortality.

During long-term follow-up, the 15-year cumulative incidence of MI was identical in both cohorts (3.5% in ANOCA vs. 3.5% in the general population). The age- and sex-adjusted incidence rate ratio showed a trend toward a lower relative risk in the ANOCA group (IRR 0.89; 95% CI: 0.81–1.00). In contrast, the risk of ischemic stroke was slightly higher in patients with ANOCA (3.7% vs. 2.9%), with an absolute risk difference of 0.8% (95% CI: 0.5–1.2).

Read also: Perforation Management in Bifurcations: Bench Testing of Bailout with Covered Stents.

All-cause mortality was slightly lower in the ANOCA cohort compared with the general population (25.4% vs. 26.3%), with an absolute difference of −0.9% (95% CI: −1.8 to −0.1) and an IRR of 0.86 (95% CI: 0.83–0.90).

Stratified analyses showed that men and older patients (≥75 years) had more favorable risk profiles compared with the general population. In contrast, a specific subgroup—patients with diffuse non-obstructive coronary artery disease—exhibited a significantly increased risk of MI, ischemic stroke, and mortality, clearly differentiating them from patients with minimal or no coronary disease.

Conclusions

In this population-based observational study, patients with ANOCA exhibited a 15-year risk of MI similar to that of the general population, a slightly lower overall mortality, and a modestly increased risk of ischemic stroke. Importantly, subgroups with higher vulnerability were identified—particularly younger patients, women, and those with diffuse non-obstructive coronary artery disease—highlighting the need for more precise risk stratification in this population.

Original Title: 15-Year Cardiovascular Risk in Patients With Angina Without Obstructive Coronary Arteries.

Reference: Olesen KKW, Madsen M, Würtz M, Thim T, Mortensen MB, Sørensen HT, Maeng M. 15-Year Cardiovascular Risk in Patients With Angina Without Obstructive Coronary Arteries. JACC Cardiovasc Interv. 2025 Dec 22;18(24):3009-3020. doi: 10.1016/j.jcin.2025.09.014. Epub 2025 Nov 14. PMID: 41240023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Bioresorbable devices vs DES in patients at high risk of restenosis. Seven-year follow-up of the COMPARE-ABSORB trial

Studies with second-generation drug-eluting stents (DES) have shown that the rate of target lesion failure (TLF) increases linearly up to 5–10 years of follow-up,...

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...